MiNK Therapeutics, Inc. (INKT): Nasdaq/NYSE listing notice — MiNK receives Nasdaq deficiency notices for MVLS and minimum bid price; faces potential delisting

MiNK Therapeutics, Inc.

On Feb 23, 2024, Nasdaq notified MiNK that its MVLS was below $35M for 30 consecutive days; compliance deadline Aug 21, 2024.
On Feb 26, 2024, Nasdaq notified MiNK that its common stock bid price closed below $1.00 for 30 consecutive days; deadline Aug 26, 2024.
To regain MVLS compliance, MVLS must be ≥$35M for 10 consecutive days; failure may lead to delisting with appeal rights.
To regain bid price compliance, stock must close at ≥$1.00 for 10 consecutive days; possible additional 180-day cure period if eligible.
MiNK is evaluating options to regain compliance but provides no assurance of success.

item 3.01

Key facts

Extracted from this filing and checked against the source text.

Listing & Compliance Notices SEC 8-K Item 3.01 confidence 0.95

MiNK Therapeutics, Inc. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5550(a)(2)).

Exchange: nasdaq
Notice: deficiency notice
Deficiency: minimum bid price
Rules: 5550(a)(2)

Exact text from the filing

February 26, 2024, the Company received a letter (the “Minimum Bid Price Notice”) from Nasdaq notifying the Company that its Class A common stock, $0.0001 par value per share (the “Common Stock”), failed to comply with the $1 minimum bid price required for continued listing on The Nasdaq Capital Market under Nasdaq Listing Rule 5550(a)(2) (the “Minimum Bid Price Rule”) based upon the closing bid price of the Common Stock for the 30 consecutive trading days prior to the date of the Minimum Bid Price Notice from Nasdaq. The Company has been provided an initial compliance period of 180 calendar d

View on SEC.gov

Browse all listing & compliance notices →

MiNK Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0000950170-24-023061

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.